Sight Sciences Inc Stock News

Sight Sciences, Inc. (NASDAQ:SGHT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT Company Participants Paul Badawi - Co-Founder, President, CEO & Director Alison Bauerlein - CFO, Principal Financial & Accounting Officer and Treasurer Presentation Unknown Analyst Awesome. Thank you so much.

UnitedHealthcare's Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically necessary UnitedHealthcare's Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically necessary

This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical data This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical data

MENLO PARK, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New Yor...

Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alison Perry Bauerlein - CFO, Principal Financial & Accounting Officer and Treasurer Matthew W. Link - Chief Commercial Officer Paul Badawi - Co-Founder, President, CEO & Director Conference Call Participants Danielle Joy Antalffy - UBS Investment Bank, Research Division Frank Jam...

MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the second quarter ended June 30, 2025, and raised its revenue guidan...

Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research

Mean signs and symptoms for participants in Stage 3 of the SAHARA trial remained statistically significantly better than study baseline at all time points measured up to 24 months Mean signs and symptoms for participants in Stage 3 of the SAHARA trial remained statistically significantly better than study baseline at all time points measured up to 24 months